Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Biotage AB ( (SE:BIOT) ) has issued an update.
Biotage AB has re-classified 2,611 class C shares to ordinary shares as part of its long-term incentive plan from 2022. This re-classification has increased the total number of votes in the company by 2,349.9, while the total number of shares remains unchanged, reflecting a strategic move to fulfill commitments to participants in the incentive plan.
More about Biotage AB
Biotage is a global supplier and solutions partner specializing in Drug Discovery and Development and Analytical Testing. The company focuses on separation and purification technology and intelligent workflow solutions to advance health solutions. Headquartered in Sweden, Biotage operates in over 80 countries and is listed on NASDAQ Stockholm.
Average Trading Volume: 716,420
Current Market Cap: SEK11.34B
For an in-depth examination of BIOT stock, go to TipRanks’ Stock Analysis page.